Research Triangle Park, North Carolina, March 16, 2026
IQVIA Holdings Inc. announced the launch of IQVIA.ai, a next-generation unified agentic AI platform developed in collaboration with NVIDIA to enhance decision-making, operational efficiency, and innovation across the life sciences industry. The platform integrates IQVIA’s Healthcare-grade AI®, proprietary data assets, and advanced analytics with NVIDIA technologies including Nemotron, NeMo Agent Toolkit, Dynamo, and LangChain, creating a scalable and secure infrastructure designed to meet the stringent requirements of regulated healthcare environments.
Unified AI Platform Driving Intelligent Decision-Making
IQVIA.ai represents a significant advancement in enterprise-level artificial intelligence for life sciences, acting as a centralized digital command center that combines AI-driven automation, advanced analytics, and decision support systems into a single unified interface. The platform enables organizations to embed intelligence directly into workflows, allowing seamless integration across clinical research, commercial operations, and real-world data analysis.
By orchestrating tasks across multiple datasets and functions, IQVIA.ai helps organizations accelerate research processes, streamline operations, and make faster, data-driven decisions. Its agentic AI architecture continuously learns from operational feedback, ensuring adaptive performance and improved accuracy over time while maintaining high standards of privacy, regulatory compliance, and data security.
Accelerating Clinical Research and Industry Transformation
Advertisement
The platform is designed to address the growing complexity and volume of data in life sciences, enabling pharmaceutical, biotech, and healthcare organizations to transform raw data into actionable insights at scale. IQVIA.ai supports clinical trial optimization, commercial intelligence, and real-world evidence generation, significantly improving efficiency across the product lifecycle. With more than 150 intelligent AI agents already deployed and adoption by 19 of the top 20 pharmaceutical companies, the platform demonstrates strong industry acceptance and trust. IQVIA has also filed over 100 AI-related patents, reflecting its commitment to innovation in AI-driven healthcare solutions.
By integrating conversational AI with configurable agents tailored to real-world workflows, the platform enables users to securely deploy and scale AI tools, enhancing productivity while ensuring compliance with healthcare regulatory and quality standards.
Scalable, Secure, and Future-Ready AI Infrastructure
Built on decades of experience in clinical research services and healthcare intelligence, IQVIA.ai provides a future-ready infrastructure capable of supporting the evolving needs of the life sciences ecosystem. The platform’s design emphasizes responsible AI adoption, ensuring that all processes align with privacy regulations, patient safety requirements, and industry compliance standards. Its ability to unify data, analytics, and AI-driven workflows under a single architecture enables organizations to unlock greater value from complex datasets and improve strategic decision-making.
The initial release focuses on high-impact use cases across clinical, commercial, and real-world domains, with additional capabilities and AI agents expected to be introduced in subsequent phases. As AI continues to reshape the healthcare landscape, IQVIA.ai positions itself as a critical enabler of digital transformation, helping organizations accelerate the development and commercialization of innovative medical solutions.
Source: IQVIA press release
